keyword
MENU ▼
Read by QxMD icon Read
search

Bevacizumab

keyword
https://www.readbyqxmd.com/read/28934120/angiogenesis-inhibitors-in-nsclc
#1
REVIEW
Anna Manzo, Agnese Montanino, Guido Carillio, Raffaele Costanzo, Claudia Sandomenico, Nicola Normanno, Maria Carmela Piccirillo, Gennaro Daniele, Francesco Perrone, Gaetano Rocco, Alessandro Morabito
Angiogenesis is a complex biological process that plays a relevant role in sustaining the microenvironment, growth, and metastatic potential of several tumors, including non-small cell lung cancer (NSCLC). Bevacizumab was the first angiogenesis inhibitor approved for the treatment of patients with advanced NSCLC in combination with chemotherapy; however, it was limited to patients with non-squamous histology and first-line setting. Approval was based on the results of two phase III trials (ECOG4599 and AVAIL) that demonstrated an improvement of about two months in progression-free survival (PFS) in both trials, and in the ECOG4599 trial, an improvement in overall survival (OS) also...
September 21, 2017: International Journal of Molecular Sciences
https://www.readbyqxmd.com/read/28933580/the-role-of-cediranib-in-ovarian-cancer
#2
Cecilia Orbegoso, Gloria Marquina, Angela George, Susana Banerjee
Treatment options for relapsed ovarian cancer have increased over the decade with the addition of targeted agents, such as PARP inhibitors and antiangiogenic agents. Bevacizumab, a monoclonal antibody binding vascular endothelial growth factor (VEGF), was the first anti-angiogenic agent to be incorporated in the ovarian cancer treatment landscape. Other molecules utilising different mechanisms of action to target angiogenesis have been developed, including Cediranib, an oral potent inhibitor of VEGF Tyrosine Kinase Inhibitor that has demonstrated activity in both phase II and phase III studies...
September 21, 2017: Expert Opinion on Pharmacotherapy
https://www.readbyqxmd.com/read/28932193/safety-profile-of-anticancer-and-immune-modulating-biotech-drugs-used-in-a-real-world-setting-in-campania-region-italy-bio-cam-observational-study
#3
Cristina Scavone, Liberata Sportiello, Maria G Sullo, Carmen Ferrajolo, Rosanna Ruggiero, Maurizio Sessa, Pasquale M Berrino, Gabriella di Mauro, Liberato Berrino, Francesco Rossi, Concetta Rafaniello, Annalisa Capuano
Objectives: To investigate the occurrence of adverse events (AEs) in naïve patients receiving biotech drugs. Design: A prospective observational study. Setting: Onco-hematology, Hepato-gastroenterology, Rheumatology, Dermatology, and Neurology Units in Campania Region (Italy). Participants: 775 patients (53.81% female) with mean age 56.0 (SD 15.2). The mean follow-up/patient was 3.48 (95% confidence interval 3.13-3.84). Main outcome measures: We collected all AEs associated to biotech drugs, including serious infections and malignancies...
2017: Frontiers in Pharmacology
https://www.readbyqxmd.com/read/28932083/integrating-tyms-kras-and-braf-testing-in-patients-with-metastatic-colorectal-cancer
#4
Anastasios Ntavatzikos, Aris Spathis, Paul Patapis, Nikolaos Machairas, George Peros, Stefanos Konstantoudakis, Danai Leventakou, Ioannis G Panayiotides, Petros Karakitsos, Anna Koumarianou
AIM: To investigate the impact of thymidylate synthase (TYMS), KRAS and BRAF in the survival of metastatic colorectal cancer (mCRC) patients treated with chemotherapy. METHODS: Clinical data were collected retrospectively from records of consecutive patients with mCRC treated with fluoropyrimidine-based chemotherapy from 1/2005 to 1/2007. Formalin-fixed paraffin-embedded tissues were retrieved for analysis. TYMS genotypes were identified with restriction fragment analysis PCR, while KRAS and BRAF mutation status was evaluated using real-time PCR assays...
August 28, 2017: World Journal of Gastroenterology: WJG
https://www.readbyqxmd.com/read/28930749/efficacy-and-safety-of-capecitabine-irinotecan-gemcitabine-and-bevacizumab-as-second-line-treatment-in-advanced-biliary-tract-cancer-a-phase-ii-study
#5
Finn Ole Larsen, Alice Markussen, Laura V Diness, Dorte Nielsen
OBJECTIVE: Since 2010, gemcitabine and cisplatin have been considered standard first-line treatment in patients with advanced biliary tract cancer. Many centers have replaced cisplatin with oxaliplatin, which seems to obtain similar results. While first-line treatment has been well established, there are no phase III trials supporting second-line treatment, and the phase II trials with chemotherapy do not show any clear benefit. In this study, we investigated the effect of adding bevacizumab to chemotherapy in second-line treatment...
September 21, 2017: Oncology
https://www.readbyqxmd.com/read/28927109/disease-progression-patterns-of-bevacizumab-responders-with-recurrent-malignant-gliomas
#6
Ju-Hwi Kim, Tae-Young Jung, Eu Chang Hwang, Sung-Hoon Jung, Shin Jung, In-Young Kim, Woo-Youl Jang, Kyung-Sub Moon, Kyung-Hwa Lee, Seul-Kee Kim
Tumor progression in patients with recurrent malignant glioma who respond to bevacizumab (BEV) is difficult to assess. The current study reviewed the clinical and radiological results of patients following a BEV-based chemotherapy regimen, and evaluated disease progression patterns in patients who responded to BEV therapy. From August 2011 to November 2015, 24 patients (18 glioblastoma cases and 6 anaplastic astrocytoma cases) were treated with BEV-based chemotherapy. In total, 6 patients were treated with BEV alone and 18 patients were treated with BEV combined with irinotecan...
September 2017: Oncology Letters
https://www.readbyqxmd.com/read/28926529/first-line-folfiri-and-bevacizumab-in-patients-with-advanced-colorectal-cancer-prospectively-stratified-according-to-serum-ldh-final-results-of-the-giscad-italian-group-for-the-study-of-digestive-tract-cancers-central-colorectalavastintrialldh-trial
#7
Riccardo Giampieri, Marco Puzzoni, Bruno Daniele, Daris Ferrari, Sara Lonardi, Alberto Zaniboni, Luigi Cavanna, Gerardo Rosati, Nicoletta Pella, Maria Giulia Zampino, Pietro Sozzi, Domenico Germano, Vittorina Zagonel, Carla Codecà, Michela Libertini, Roberto Labianca, Stefano Cascinu, Mario Scartozzi
BACKGROUND: Previous findings suggested that bevacizumab might be able to improve response rate (RR) in colorectal cancer patients with high lactic dehydrogenase (LDH) basal levels. METHODS: We conducted a phase II trial to prospectively ascertain whether bevacizumab in combination with FOLFIRI could have an improved clinical activity in patients with high LDH serum levels. Primary end point of the study was RR; secondary end points were median overall survival and median progression-free survival (mPFS)...
September 19, 2017: British Journal of Cancer
https://www.readbyqxmd.com/read/28926323/-analysis-of-the-cochrane-review-anti-vascular-endothelial-growth-factor-for-prevention-of-postoperative-vitreous-cavity-hemorrhage-after-vitrectomy-for-proliferative-diabetic-retinopathy-cochrane-database-syst-rev-2015-8-cd008214
#8
David Cordeiro Sousa, Inês Leal, João Costa, António Vaz-Carneiro
Postoperative vitreous hemorrhage is a complication following vitrectomy for proliferative diabetic retinopathy, delaying visual recovery and making fundus examination and disease follow-up more difficult. Anti-vascular endothelial growth factor drugs such as bevacizumab, when injected in the vitreous cavity, reduce vascular proliferation and their use has been proposed to reduce the incidence of postoperative vitreous hemorrhage. The authors of this Cochrane systematic review evaluated all randomized controlled trials on the pre- or intraoperative use of anti-vascular endothelial growth factor to reduce postoperative vitreous hemorrhage occurrence after vitrectomy in patients with proliferative diabetic retinopathy...
August 31, 2017: Acta Médica Portuguesa
https://www.readbyqxmd.com/read/28926190/an-8-year-follow-up-of-anti-vascular-endothelial-growth-factor-treatment-with-a-treat-and-extend-modality-for-neovascular-age-related-macular-degeneration
#9
Karina Berg, Anca B Roald, Jesintha Navaratnam, Ragnheiður Bragadóttir
PURPOSE: To investigate long-term visual results of treatment with anti-vascular endothelial growth factor (VEGF) agents for neovascular age-related macular degeneration (nAMD) following a treat-and-extend regimen. METHODS: Retrospective review of 155 patients who initiated treatment with bevacizumab for nAMD in one eye. At the final 8-year visit, 40 patients (26%) remained for follow-up. Mean change in best-corrected visual acuity (BCVA) was calculated compared to baseline values...
September 19, 2017: Acta Ophthalmologica
https://www.readbyqxmd.com/read/28925914/impact-of-travel-distance-on-access-to-treatment-and-survival-in-patients-with-metastatic-colorectal-cancer-prescribed-bevacizumab-plus-chemotherapy
#10
Evan Payette, Sabuj Sarker, Haji Chalchal
INTRODUCTION: Given Saskatchewan's size and low population density outside of city centres, many rural and remote residents have issues accessing regional oncology services. We performed a study to determine whether travel distance to cancer treatment centres affects first-line treatment accessibility and survival in patients with metastatic colorectal adenocarcinoma. METHODS: Retrospective chart review of patients with stage IV metastatic colorectal adenocarcinoma collected by the Saskatchewan Cancer Agency registry between June 1, 2009, and June 30, 2013...
2017: Canadian Journal of Rural Medicine
https://www.readbyqxmd.com/read/28925468/comparison-of-carboplatin-and-paclitaxel-with-or-without-bevacizumab-in-chemotherapeutic-regimens-for-unresectable-stage-iii-non-small-cell-lung-cancer
#11
T Ding, Z-T Li, X Zhang, Y-T Shi
OBJECTIVE: Our study aimed to compare the chemoradiotherapeutic regimens of carboplatin and paclitaxel with or without bevacizumab for stage III non-small cell lung cancer (NSCLC). PATIENTS AND METHODS: From July 2010 to December 2016, 102 patients with inoperable stage III NSCLC were finally included and divided randomly into two groups. Patients in the CP group received the treatment of carboplatin (area under the curve of 6) on day 1 and paclitaxel (80 mg/m2) on days 1, 8, and 15...
August 2017: European Review for Medical and Pharmacological Sciences
https://www.readbyqxmd.com/read/28924419/surprises-during-intravitreal-drug-delivery-a-report-of-three-cases
#12
Pradeep Venkatesh, Rohan Chawla, Bhavin Shah, Sat Pal Garg
We describe 3 cases with unusual events during and after intravitreal injection of dexamethasone intravitreal implants and bevacizumab. In case 1, delayed release of the safety stop of a dexamethasone intravitreal implant injector led to impaction and retinal break formation. Timely recognition and laser treatment prevented further retinal complications. In case 2, reinjection of a second dexamethasone intravitreal implant from the same site as the first injection was noted to dislodge the remnant of the previous implant from the vitreous base...
2017: Digital Journal of Ophthalmology: DJO
https://www.readbyqxmd.com/read/28924336/intravitreal-injections-of-bevacizumab-the-impact-of-needle-size-in-intraocular-pressure-and-pain
#13
Mónica Loureiro, Rita Matos, Paula Sepulveda, Dália Meira
AIM: To compare the effect of 30-gauge vs 27-gauge needle size on intraocular pressure (IOP) rise and patients' pain experience after intravitreal injection (IVI) of bevacizumab. MATERIALS AND METHODS: Cross-sectional, randomized, double-armed study. Patients were randomized to IVI with 30-gauge or 27-gauge needle. The IOP was measured pre and post IVI. Patients' pain was graded using the visual analog scale (VAS). RESULTS: A total of 54 eyes were included...
May 2017: Journal of Current Glaucoma Practice
https://www.readbyqxmd.com/read/28923539/efficient-vegf-targeting-delivery-of-dox-using-bevacizumab-conjugated-sio2-ldh-for-anti-neuroblastoma-therapy
#14
Rongrong Zhu, Zhaoqi Wang, Peng Liang, Xiaolie He, Xizhen Zhuang, Ruiqi Huang, Mei Wang, Qigang Wang, Yechang Qian, Shilong Wang
Vascular endothelial growth factor (VEGF) plays an important role in angiogenesis and is highly expressed in carcinoma, which make it an important target for tumor targeting therapy. Neuroblastoma is the main cause for cancer-related death in children. Like most solid tumors, it is also accompanied with the overexpression of VEGF. Doxorubicin Hydrochloride (DOX), a typical chemotherapeutic agent, exhibits efficient anticancer activities for various cancers. However, DOX, without targeting ability, usually causes severe damage to normal tissues...
September 15, 2017: Acta Biomaterialia
https://www.readbyqxmd.com/read/28923115/serous-retinal-detachment-after-panretinal-photocoagulation-for-proliferative-diabetic-retinopathy-a-case-report
#15
Patrik Schatz, Ahmed Aldayel, Ibrahim Taskintuna, Ehab Abdelkader, Marco Mura
BACKGROUND: Proliferative diabetic retinopathy is a major cause of visual impairment in working-age adults worldwide. Panretinal photocoagulation is a cornerstone in its management; however, it may include a range of side effects and complications, one of these being serous retinal detachment. To the best of our knowledge, this is the first report of the use of intravitreal injection of bevacizumab for serous retinal detachment after panretinal photocoagulation. CASE PRESENTATION: A 24-year-old Saudi man with poorly controlled type 1 diabetes presented with bilateral progressive proliferative retinopathy in spite of several sessions of panretinal photocoagulation...
September 19, 2017: Journal of Medical Case Reports
https://www.readbyqxmd.com/read/28922698/survival-improvements-with-adjuvant-therapy-in-patients-with-glioblastoma
#16
Dasantha Jayamanne, Helen Wheeler, Raymond Cook, Charles Teo, David Brazier, Geoff Schembri, Marina Kastelan, Linxin Guo, Michael F Back
BACKGROUND: Evaluate survival of patients diagnosed with glioblastoma multiforme (GBM) managed with adjuvant intensity modulated radiation therapy and temozolomide since the introduction of the European Organisation for Research and Treatment of Cancer and National Cancer Institute of Canada Clinical Trials Group (EORTC-NCIC) protocol. METHODS: All patients with GBM managed between May 2007 and December 2014 with EORTC-NCIC protocol were entered into a prospective database...
September 18, 2017: ANZ Journal of Surgery
https://www.readbyqxmd.com/read/28917648/challenges-of-conducting-a-prospective-clinical-trial-for-older-patients-lessons-learned-from-ncctg-n0949-alliance
#17
Nadine J McCleary, Joleen Hubbard, Michelle R Mahoney, Jeffrey A Meyerhardt, Daniel Sargent, Alan Venook, Axel Grothey
OBJECTIVES: While the risk of developing colorectal cancer increases with age, there are limited prospective data regarding best treatment in the older adult population. We launched a phase III trial to evaluate difference in treatment outcome for older adults (aged ≥70years) with advanced colorectal cancer. Here we review the challenges faced and reasons for poor accrual to N0949. MATERIALS AND METHODS: We describe the conceptualization, development and limited results of N0949, a randomized phase III study of fluoropyrimidine/bevacizumab with or without oxaliplatin (mFOLFOX7 or XELOX) as first line chemotherapy for metastatic colorectal cancer...
September 13, 2017: Journal of Geriatric Oncology
https://www.readbyqxmd.com/read/28915721/dramatic-response-of-ctnnb1-and-vegfr-2-mutant-temporal-bone-squamous-cell-carcinoma-to-bevacizumab-in-combination-with-pemetrexed
#18
Lai Wei, Lizhi Wang, Ziye Liu, Meiyi Wang, Weili Lu, Dewei Zhao, Bin Yang, Xuejun Kong, Yan Ding, Zhiqiang Wang
High recurrence rates and poor survival rates for late stage/advanced temporal bone squamous cell carcinoma with the standard treatments continues to be a significant challenge to otolaryngologists. Targeted therapy for temporal bone squamous cell carcinoma after relapse has not been reported. Here we present a 58-year-old man who was diagnosed with recurrent temporal bone squamous cell carcinoma and treated with a regimen developed using whole exome sequencing. Somatic mutations in genes encoding catenin beta 1 and vascular endothelial growth factor receptor 2 were identified in the patient's tumor sample compared to the normal tissue...
August 22, 2017: Oncotarget
https://www.readbyqxmd.com/read/28915674/bevacizumab-combined-with-chemotherapy-for-glioblastoma-a-meta-analysis-of-randomized-controlled-trials
#19
Shou-Bo Yang, Kai-Di Gao, Tao Jiang, Shu-Jun Cheng, Wen-Bin Li
Bevacizumab, as antibodies, were applied to inhibit tumor angiogenesis by preventing activation of vascular endothelial growth factor receptor. We analyzed four clinical trials, including 607 patients, to investigate the efficacy and safety of bevacizumab when combined with chemotherapy for the treatment of glioblastomas. Results demonstrated that bevacizumab when combined with chemotherapy improved progression-free survival (HR = 0.66; 95% CI 0.56-0.78; p < 0.00001) compared with bevacizumab or chemotherapy alone...
August 22, 2017: Oncotarget
https://www.readbyqxmd.com/read/28913305/treatment-of-tongue-lymphangioma-with-intralesional-combination-injection-of-steroid-bleomycin-and-bevacizumab
#20
Jungil Hwang, Yung Ki Lee, Jin Sik Burm
Lymphangioma is a congenital malformed lymphatic tumor that rarely involves the tongue. In our clinic, a 10-year-old female presented with lymphangioma circumscriptum involving the right two-thirds of the tongue. We administered an intralesional combination injection of triamcinolone, bleomycin, and bevacizumab as a treatment. Almost complete remission after combination therapy was achieved without complications such as edema, swallowing difficulties or recurrence. Bevacizumab, an inhibitor of vascular endothelial growth factor, was effective for the treatment of lymphangioma of the tongue in this case...
March 2017: Arch Craniofac Surg
keyword
keyword
1763
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"